One of our portfolio company, StratifAI, the AI biomarker company for precision oncology, has successfully secured €12.5 million in a new funding round.
As an existing investor, we are pleased to continue our support to StratifAI’s vision alongside other new investors. This funding will fast-track the clinical validation and global expansion of their multimodal AI biomarker discovery platform, Polaris™.
Polaris™ is set to revolutionize cancer diagnostics by leveraging multimodal AI to gain critical spatial insights directly from routine histology, identifying novel prognostic and predictive biomarkers. This fully digital, AI-driven approach is key to enabling more equitable and individualized treatment strategies across solid-tumor cancers.
Learn more about Polaris™ and StratifAI’s vision here